Raloxifene (Evista): Uses, Dosing, Side Effects, and How It Compares to Bisphosphonates

What Is Raloxifene and How Does It Work?

Raloxifene is a selective estrogen receptor modulator that mimics estrogen's protective effects on bone while blocking estrogen activity in breast and uterine tissue. The FDA approved it in 1997 for osteoporosis prevention and added a treatment indication in 1999, followed by a breast cancer risk-reduction indication in 2007 [1]. It binds estrogen receptors in a tissue-specific pattern. Bone and lipid metabolism see agonist activity. Breast and uterine tissue see antagonist activity.

At the molecular level, raloxifene suppresses osteoclast-mediated bone resorption by reducing receptor activator of nuclear factor kappa-B ligand (RANKL) expression [2]. This mechanism differs fundamentally from bisphosphonates like alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), and zoledronic acid (Reclast), which kill osteoclasts directly by disrupting the mevalonate pathway. The clinical consequence of that mechanistic difference is measurable: raloxifene produces more modest gains in bone mineral density (BMD), typically 2 to 3 percent at the lumbar spine over three years, compared to 5 to 8 percent with oral bisphosphonates [3]. BMD gain alone does not tell the full story, though. Raloxifene's fracture reduction appears to exceed what its BMD change would predict, suggesting effects on bone quality beyond density [4].

The drug reaches peak plasma concentration within 0.5 to 6 hours and has an oral bioavailability of roughly 2 percent after extensive first-pass glucuronidation [1]. Its 27.7-hour half-life supports once-daily dosing. No dose adjustment is needed for mild renal impairment, but the drug has not been studied in patients with severe hepatic dysfunction.

Fracture Protection: What the Trials Actually Show

Raloxifene reduces new vertebral fractures by 30 to 50 percent in postmenopausal women with osteoporosis, but it has never demonstrated efficacy against hip fractures in any randomized controlled trial. That single distinction shapes every prescribing decision.

The MORE trial (Multiple Outcomes of Raloxifene Evaluation, N=7,705) randomized postmenopausal women with osteoporosis to raloxifene 60 mg, raloxifene 120 mg, or placebo for three years [3]. At the 60 mg dose, the relative risk of new vertebral fracture was 0.70 (95% CI 0.56 to 0.86). Women without prevalent vertebral fractures at baseline saw a 55 percent reduction. Women with existing fractures saw a 30 percent reduction. The number needed to treat (NNT) to prevent one vertebral fracture over three years was 46 for the lower-risk group and 16 for the higher-risk group.

Nonvertebral fractures, including hip fractures, did not decrease significantly (RR 0.92 to 95% CI 0.79 to 1.07) [3]. The CORE extension study followed 4,011 women from MORE for an additional four years and confirmed ongoing vertebral protection but no hip fracture benefit [5].

This evidence creates a clear clinical decision framework. The Endocrine Society's 2019 guideline states: "Raloxifene is recommended for postmenopausal women with osteoporosis at high risk for vertebral fracture when bisphosphonates are not appropriate" [6]. The American Association of Clinical Endocrinologists (AACE) 2020 guideline echoes this, classifying raloxifene as appropriate for patients at "low-to-moderate fracture risk" and explicitly recommending bisphosphonates, denosumab, or anabolic agents for patients at high hip fracture risk [7].

The Breast Cancer Bonus: STAR Trial Data

One of the strongest arguments for choosing raloxifene over a bisphosphonate is the concurrent reduction in invasive breast cancer risk, a benefit no bisphosphonate can match.

The STAR trial (Study of Tamoxifen and Raloxifene, N=19,747) compared raloxifene 60 mg daily with tamoxifen 20 mg daily in postmenopausal women at increased breast cancer risk [8]. Over a median follow-up of 3.9 years, raloxifene reduced invasive breast cancer incidence by 44 percent relative to placebo projections. Initial results showed raloxifene was about as effective as tamoxifen for invasive cancer prevention (RR 1.02 to 95% CI 0.82 to 1.28), though long-term follow-up at 81 months suggested tamoxifen retained a slight edge for noninvasive cancers [9].

Dr. Victor Vogel, lead author of the STAR update, noted: "Raloxifene retained 76 percent of the effectiveness of tamoxifen in preventing invasive breast cancer, with fewer thromboembolic events and cataracts" [9]. For a postmenopausal woman facing both osteoporosis and elevated breast cancer risk (Gail score ≥1.66%), raloxifene addresses two problems with a single 60 mg tablet. That dual benefit has real clinical value. A woman who might otherwise need a bisphosphonate plus tamoxifen can sometimes use raloxifene alone.

The Ruth trial (Raloxifene Use for The Heart, N=10,101) confirmed the breast cancer reduction in an older population with coronary risk factors, showing a 44 percent decrease in invasive breast cancer over a median 5.6 years (HR 0.56 to 95% CI 0.38 to 0.83) [10].

Raloxifene vs. Alendronate (Fosamax)

Alendronate is the most widely prescribed oral bisphosphonate and the most common alternative to raloxifene for postmenopausal osteoporosis. The choice between them depends on fracture site risk, gastrointestinal tolerance, and whether breast cancer prevention matters.

The FIT trial (Fracture Intervention Trial, N=6,459) demonstrated that alendronate 10 mg daily reduced hip fractures by 51 percent (RR 0.49 to 95% CI 0.23 to 0.99) and vertebral fractures by 47 percent over three years in women with existing vertebral fractures [11]. That hip fracture reduction is the key differentiator. Raloxifene cannot match it.

BMD gains also diverge. Alendronate typically increases lumbar spine BMD by 6 to 8 percent over three years versus raloxifene's 2 to 3 percent [3][11]. At the femoral neck, alendronate produces roughly 3 to 5 percent gains compared to raloxifene's 1 to 2 percent.

Side effect profiles differ sharply. Alendronate carries a well-documented risk of esophagitis, esophageal ulceration, and upper GI symptoms that require strict dosing instructions (taken fasting, upright for 30 minutes, with 8 ounces of water) [12]. Raloxifene has no GI requirements. A woman with Barrett's esophagus or severe GERD who needs skeletal protection may find raloxifene far more practical.

Alendronate use beyond five years raises concerns about atypical femoral fractures (AFFs) and osteonecrosis of the jaw (ONJ). The FDA's 2022 review estimated AFF incidence at 1.78 per 100,000 person-years for short-term use, rising to 113 per 100,000 person-years after 8 or more years [13]. Raloxifene carries no AFF or ONJ risk. For this reason, patients who have completed a bisphosphonate course and need ongoing protection sometimes transition to raloxifene during what would otherwise be a drug holiday.

Raloxifene vs. Risedronate (Actonel), Ibandronate (Boniva), and Zoledronic Acid (Reclast)

Each bisphosphonate brings a distinct efficacy and convenience profile that warrants comparison with raloxifene.

Risedronate (Actonel) reduced hip fractures by 40 percent over three years in the HIP trial (N=9,331) among women aged 70 to 79 with confirmed osteoporosis [14]. Its vertebral fracture reduction (41 to 49 percent over three years in the VERT trials) is comparable to alendronate [15]. Risedronate shares alendronate's GI limitations and AFF concerns. A weekly 35 mg tablet or monthly 150 mg option exists. Like alendronate, risedronate is preferred over raloxifene when hip fracture risk is meaningful.

Ibandronate (Boniva) has proven vertebral fracture efficacy (52 percent reduction in the BONE trial, N=2,946) but, like raloxifene, lacks hip fracture data from randomized trials [16]. This makes ibandronate a weaker choice than alendronate or risedronate when hip protection matters. Available as a monthly 150 mg oral tablet or quarterly 3 mg IV injection, ibandronate occupies a narrow niche. Choosing between ibandronate and raloxifene comes down to whether breast cancer chemoprevention tips the balance.

Zoledronic acid (Reclast) is the most potent bisphosphonate available. In the HORIZON-PFT trial (N=7,765), a single 5 mg IV infusion annually reduced hip fractures by 41 percent (RR 0.59 to 95% CI 0.42 to 0.83), vertebral fractures by 70 percent, and nonvertebral fractures by 25 percent over three years [17]. The AACE 2020 guideline recommends zoledronic acid as a first-line option for high-risk and very-high-risk patients [7]. Raloxifene cannot compete with these numbers. The practical advantages of raloxifene (oral daily dosing, no infusion center visit, no bisphosphonate-class risks) matter only when fracture risk is low enough to justify accepting less antifracture efficacy.

Side Effects and Safety Considerations

Raloxifene's most serious risk is venous thromboembolism (VTE). The MORE trial reported a VTE relative risk of 3.1 (95% CI 1.5 to 6.2) during the first four months, decreasing to 1.44 over the full three-year period [3]. The absolute excess risk was approximately 1.5 additional VTE events per 1,000 women per year. The RUTH trial confirmed this signal, with a VTE hazard ratio of 1.44 (95% CI 1.06 to 1.95) [10].

Hot flashes occur more frequently with raloxifene than with placebo or bisphosphonates. In MORE, 9.7 percent of raloxifene-treated women reported hot flashes versus 6.4 percent on placebo [3]. This is a meaningful nuisance side effect in early postmenopausal women already experiencing vasomotor symptoms. Leg cramps affected 5.5 percent of the raloxifene group versus 1.9 percent on placebo.

The drug does not stimulate the endometrium. Unlike tamoxifen, raloxifene does not increase endometrial cancer risk [8]. It also does not cause vaginal bleeding. This uterine safety profile is one reason the FDA approved it for postmenopausal women without requiring endometrial monitoring.

According to the Endocrine Society's 2019 clinical practice guideline: "Raloxifene should not be used in women with a history of VTE or those at high risk of VTE, including prolonged immobilization" [6]. Patients should discontinue raloxifene at least 72 hours before prolonged immobility (such as a long flight or scheduled surgery) and not restart until full mobility returns.

Raloxifene modestly lowers LDL cholesterol (6 to 10 percent reduction) without raising triglycerides or HDL significantly [10]. The RUTH trial, however, showed no reduction in cardiovascular events despite this lipid effect (HR 0.95 to 95% CI 0.84 to 1.07 for coronary events) [10]. Clinicians should not prescribe raloxifene expecting a cardiac benefit.

Dosing, Administration, and Duration

The FDA-approved dose is 60 mg orally once daily. No titration is needed. The tablet can be taken with or without food, at any time of day. This simplicity is a genuine advantage over oral bisphosphonates, which demand fasting administration with specific positioning requirements.

Calcium (1,000 to 1 to 200 mg daily from diet plus supplements) and vitamin D (800 to 2 to 000 IU daily) should accompany raloxifene therapy. Baseline 25-hydroxyvitamin D levels should be checked and corrected to above 30 ng/mL before starting treatment [7].

There is no mandatory drug holiday for raloxifene. Unlike bisphosphonates, raloxifene does not accumulate in bone matrix, so its effects dissipate within weeks of discontinuation. The MORE/CORE studies showed continued efficacy through 7 years of uninterrupted use [5]. Many clinicians continue raloxifene indefinitely in women who tolerate it well and retain a vertebral fracture risk profile, reassessing every 3 to 5 years with DXA and FRAX scoring.

For women transitioning off bisphosphonates, raloxifene can serve as sequential therapy. A common clinical pattern: 5 years of alendronate, then reassessment. If the patient's T-score has improved to >-2.5 and her 10-year hip fracture probability (FRAX) is below 3 percent, switching to raloxifene maintains vertebral protection while avoiding extended bisphosphonate exposure [7].

Who Is the Right Candidate for Raloxifene?

Not every postmenopausal woman with osteoporosis should take raloxifene. The drug fits a specific clinical profile, and matching the right patient to the right medication matters more than choosing the "strongest" option.

The strongest candidate is a postmenopausal woman with osteoporosis or osteopenia (T-score between -1.0 and -2.5) whose FRAX 10-year hip fracture probability is below 3 percent and major osteoporotic fracture probability is below 20 percent. She has no history of VTE. She has completed menopause long enough that hot flashes have subsided. She may have elevated breast cancer risk (family history, atypical ductal hyperplasia, high breast density, or Gail model score ≥1.66%).

A less suitable candidate is a woman with high hip fracture risk, a history of DVT or pulmonary embolism, active vasomotor symptoms, or a need for broad nonvertebral fracture protection. These patients are better served by alendronate, risedronate, zoledronic acid, or denosumab.

The prescribing decision is not raloxifene versus nothing. It is raloxifene versus a specific alternative. Every treatment plan should include the patient's FRAX score, DXA results, VTE history, breast cancer risk assessment, GI tolerance, and preferences about dosing convenience.

Monitoring on raloxifene includes DXA every 2 years, annual height measurement (loss of >2 cm suggests occult vertebral fracture), and clinical reassessment of VTE risk factors at each visit. Bone turnover markers (CTX, P1NP) are optional but can confirm treatment response within 3 to 6 months.